Experimental MS treatment offered to select patients
NCT ID NCT04081714
Summary
This program provides early access to an experimental oral treatment called CNM-Au8 for up to 25 people with multiple sclerosis. Participants will take the medication daily for 96 weeks while doctors monitor their safety and how well the treatment works. The program is designed for people whose current standard treatments aren't adequately controlling their MS progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern
Dallas, Texas, 75235, United States
Conditions
Explore the condition pages connected to this study.